Background Evaluation of treatment options for localized prostate cancer (PCa) remains
among the highest priorities for comparative effectiveness research. Surgery and …

Purpose SpaceOAR, a Food and Drug Administration–approved hydrogel intended to create
a rectal–prostate space, was evaluated in a single-blind phase III trial of image guided …

Background Brachytherapy boost after external beam radiotherapy for intermediate and high-
risk prostate cancer is presented as an attractive technique in numerous retrospective and …

Following adoption of moderately hypofractionated radiotherapy as a standard for localised
prostate cancer, ultrahypofractioned radiotherapy delivered in five to seven fractions is …

Low dose rate (LDR) prostate brachytherapy is an evidence based radiation technique with
excellent oncologic outcomes. By utilizing direct image guidance for radioactive source …

Purpose The use of prostate brachytherapy has continued to decline in the United States.
We examined the national practice patterns of both academic and nonacademic practices …

Abstract Background and Purpose Long-term toxicity of high dose-rate brachytherapy as
monotherapy for prostate cancer is not well defined. We report late toxicity and health …

High-dose-rate brachytherapy (HDR BT) is a radiation therapy that places radioactive
sources at cancerous tissue using needles. HDR BT offers better dose conformality and …

Purpose To report outcomes of patients undergoing low-dose-rate (LDR) brachytherapy and
investigate factors associated with biochemical failure and survival. Methods Consecutive …

Purpose Androgen suppression combined with elective nodal and dose-escalated radiation
therapy recently demonstrated an improved biochemical failure–free survival in men who …